Vazyme Biotech Co., Ltd (SHA: 688105), a prominent biotech company based in China, has entered into a strategic partnership with SPH KDL Health to enhance the distribution and promotion of its Alzheimer’s disease (AD) blood test products. The collaboration may lead to the signing of a separate product agency agreement based on practical business requirements.
Under this partnership, the two companies will work together to advance academic education, establish expert consensus, and promote clinical adoption of the AD blood test products in their respective regions. Additionally, they plan to collaborate on respiratory pathogen testing products within the agreed-upon provincial and municipal territories. The financial details of the agreement were not disclosed.- Flcube.com
